Madrid

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting
  2023-504013-68-00 1 2024-09-06 Advanced or Metastatic Prostate Cancer
• A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy … Recruiting
  2024-511074-80-01 7 2024-09-06 Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refrac
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i … Recruiting
  2023-504647-14-00 4 2024-09-02 Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• Phase 1 Study of PYX-201 in Solid Tumors Recruiting
  2023-509687-14-00 1 2024-08-29 Advanced solid tumors
• Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting
  2023-507692-21-00 3 2024-08-22 Bullous pemphigoid
• An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tum … Recruiting
  2022-502757-34-00 1 2024-08-20 Advanced solid tumors
• Effectiveness and safety of combined autologous Platelet Rich Plasma and Focal Shockwave Therapy for the treatment of erectile dysfunction Recruiting
  2024-517248-73-00 11 2024-08-19 Erectile dysfunction
• First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting
  2023-508435-31-00 1 2024-08-09 Advanced Solid Tumors, Advanced Breast Cancer
• Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancrea … Recruiting
  2024-512742-42-00 4 2024-08-09 Pancreatic carcinoma
• A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli … Recruiting
  2023-506199-28-00 1 2024-08-05 Dose escalation: Advanced Solid Tumors Dose Expansion: Squamous non-sm
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting
  2023-508703-21-00 9 2024-08-01 Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), bili
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug … Recruiting
  2023-504898-20-00 4 2024-07-30 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iodine refractory
• A PHASE I STUDY OF XXX AS SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN SOLID CANCERS AND A RANDOMIZED COHORT EXPLORING THE COMB … Recruiting
  2024-512175-12-00 1 2024-07-29 Low tumour volume (LTV) advanced, metastatic, or recurrent solid malig
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and … Recruiting
  2023-508482-32-00 5 2024-07-22 Neutropenias
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on … Recruiting
  2022-502135-19-00 4 2024-07-18 Calcific Aortic Valve Stenosis
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent

Showing 1,297–1,320 of 3,550 trials